Special Announcement - Now Screening for FDA Approved Stem Cell Study
Dr. Mitchell Sheinkop has completed training and is credentialed for an FDA-approved stem cell clinical trial for knee arthritis. Our clinic is now screening patients for this trial. Contact us at 312-475-1893 for details. Click here to learn more.

Patient Completes Grand Canyon Rim to Rim Hike

Mitch,

I wanted to let you know I completed the 4 day Grand Canyon Rim to Rim hike.  The descent was horrible on my knees and ascent was hard on the heart….but I DID IT!!!!

Knees feel good today- you saved me and made it possible to accomplish such an incredible adventure.

THANK YOU!
❤️

Penny

Bike riding is back to being a pleasure!

Hello Dr. Sheinkop,

I noticed more improvement Thursday. Bike riding is a pleasure. Once again, there wasn’t any discomfort with the hills.

I’m very grateful for your assistance in my recovery. See you in October.

My best,
Janis

Knee Study Patient Provides an Update

Hello Dr. Sheinkop,

I wanted to let you know that my knee is feeling much better. I have been able to start exercising again, as well as play some basketball. It is a little sore afterwards and there’s sometimes pain when I jump my hardest, but it is still an incredible improvement! Moreover, it keeps getting better as my leg strength increases. Just wanted to say thank you again for accepting me into the study!

Also, I was accepted to the Southern Illinois School of Medicine Class of 2020 several months ago and will begin classes this August! Guess I will be seeing you this Fall, so I will be sure to let you know how everything is going. See you then!

Regards,

Gary

Knee improvement update from stem cell study patient

Hello Dr. Sheinkop,

I wanted to let you know that my knee is feeling much better. I have been able to start exercising again, as well as play some basketball. It is a little sore afterwards and there’s sometimes pain when I jump my hardest, but it is still an incredible improvement! Moreover, it keeps getting better as my leg strength increases. Just wanted to say thank you again for accepting me into the study!

Also, I was accepted to the Southern Illinois School of Medicine Class of 2020 several months ago and will begin classes this August! Guess I will be seeing you this Fall, so I will be sure to let you know how everything is going. See you then!

Regards,
Gary

Accuracy, Ethics and Corrections

The last Blog posted in 2015 indicated that I wouldn’t look back; but after its posting, I received this correction form Dr Chris Centeno, arguably, the best informed Regenerative Medicine expert in the North America.

“Mitch,

The discussion of amniotic injections isn’t correct. We found that amniotic tissue hurt stem cells. While we did find a weak growth factor/cytokine effect, it was less than PRP. So extrapolating that data, it would be stem cells>PRP>amniotic. Please correct.

Chris”

I very much appreciate his input as well as invite his ongoing constructive criticism, additions and recommended corrections. Let me add, the PRP he is referring to is not the usual and customary office based 15 minute procedure; but rather a proprietary process developed in the Regenexx laboratories and available from those physician members of the Regenexx network.

 

Changing my focus, in a review article appearing in the January 2016, volume of the Journal of the American Academy of Orthopedic Surgeons, an article appeared Risk Prediction Tools for Hip and Knee Arthroplasty. It is easier for me to quote rather than extrapolate:  “After arthroplasty, complications such as infection, venous thromboembolism, acute myocardial infarction, pneumonia and many others are associated with poorer patient outcomes and represent a substantial cost burden to the American healthcare system”. The article continues: “Total joint arthroplasty is thus an appropriate target for quality improvement and cost containment via pay-for-performance initiatives.” For someone such as myself, an orthopedic surgeon who devoted a 37 year career after nine years of post graduate education and training performing Total Joint Replacements, I feel that my professional evolution into cellular orthopedics is again validated.  In reviewing our data base, following a cellular orthopedic intervention for arthritis, we have not recorded one infection, venous thromboembolism, acute myocardial infarction, case of pneumonia, or any other complication. While 100% of my patients do not experience a successful or satisfactory outcome following the first cellular orthopedic intervention for arthritis, those numbers increase from 75% to 85% with a booster or repeat procedure. Once again, the end result of an unsuccessful Total Joint Replacement is a revision surgery; after a revision, it was not unusual to hear a patient volunteer “give me back my arthritis”. After a less than optimal outcome of a cellular orthopedic intervention, the fallback position is a repeat procedure followed by a patient’s “thank you doctor.”

Tags: , , , , , , , , , , , , , , , , , , , , , ,

Interventional Orthopedic Inclusion and Exclusion Criteria

Interventional Orthopedic Inclusion and Exclusion Criteria

Why our Regenerative Medicine/Interventional Orthopedic clinical practice is where you should consult before undergoing a Cellular Medicine intervention:

I am an orthopedic surgeon, Professor Emeritus at Rush, who for 37 years, performed Joint Replacement Surgery for arthritis before “graduating” into Cellular Orthopedics. Basically, I exchanged my knife for a needle. As a Fellow of the American Academy of Orthopedic Surgeons, I am required to partake in the Mandatory Disclosure Policy requiring me to update disclosures and potential conflicts of interest at least semiannually (April and October). All AAOS members involved as continued medical education faculty and authors, orthopedic volunteers in organizational governance, clinical practice guidelines, appropriate use criteria, and performance measures development, and editors-in-chief and members of editorial boards are required to complete disclosure in the AAOS Orthopedic Disclosure Program. My membership and active participation in the American Academy of Orthopedic Surgeons, my Fellowship in the American College of Surgeons, and my membership in the American Medical Association is your quality assurance that I subscribe to evidence based clinical practice guidelines. As such, it is my responsibility to offer Regenerative Medicine interventions to only those who meet Inclusion Criteria and educate patients who I can’t help about joint replacement alternatives. Furthermore, I also am bound by professional ethics not to add unproven treatments to my range of services.

Inclusion criteria are based on a medical history and physical examination, first and foremost and secondarily, after a look at an X-ray or MRI. Conversely, we employ a relatively strict list of exclusion criteria for those patients who just won’t benefit from Cellular Orthopedic interventions. Admittedly, while our practice is based on the scientific evidence, from time to time there are new treatment options. Unlike many who offer stem cell treatments, when a new regenerative option is brought to my attention, if I feel that it falls within FDA approved guidelines, I will investigate, apply for an IRB centered scrutiny and provide exhaustive informed consent to a patient. Your quality assurance of my standards of practice should also be reinforced by my participation as a member of the Regenexx Network and my involvement in the recently formed Regenexx Board of Advisors. In addition, I have made a commitment to my patients that I would become familiar with any new clinical trial initiatives and participate if I feel there is a role for such in my practice.

Over the next several weeks, I will share with you my review of new Regenerative Offerings, especially for those who might otherwise not meet our Regenexx inclusion criteria.

Tags: , , , , , , , , , , , , , , , , ,

Pin It on Pinterest